An article reports on a presentation at a cancer symposium:
A study of 792 men with a testosterone level of 350 ng/dL or less. Of these, 412 received testosterone undecanoate 1000 mg every 3 months for up to 12 years and 380 opted against receiving TRT (control group). The median follow-up was 9 years, and the total observation time covered approximately 6400 patient-years. Eleven men in the TRT group (2.7%) were diagnosed with PCa [prostate cancer] compared with 34 men (8.9%) in the control group. The incidence of PCa was 33 cases per 10,000 person-years in the TRT group versus 108 per person-years in the control group.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
